Inactive Instrument

Hansa Biopharma AB Share Price Nasdaq Stockholm

Equities

SE0002148817

Biotechnology & Medical Research

Real-time Estimate Cboe Europe 13:23:13 27/05/2024 BST 5-day change 1st Jan Change
38.73 SEK -76.28% Intraday chart for Hansa Biopharma AB -5.78% -38.73%

Financials

Sales 2024 * 239M 22.5M 1.76B Sales 2025 * 343M 32.23M 2.53B Capitalization 2.59B 243M 19.09B
Net income 2024 * -735M -69.12M -5.42B Net income 2025 * -712M -66.96M -5.25B EV / Sales 2024 * 12.8 x
Net Debt 2024 * 474M 44.58M 3.5B Net Debt 2025 * 733M 68.97M 5.41B EV / Sales 2025 * 9.7 x
P/E ratio 2024 *
-3.56 x
P/E ratio 2025 *
-4.22 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 88.64%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 59 19/03/18
Chief Tech/Sci/R&D Officer 53 11-30
Chief Tech/Sci/R&D Officer 66 28/05/20
Members of the board TitleAgeSince
Director/Board Member 73 28/05/18
Chairman 61 29/06/22
Director/Board Member 59 21/05/19
More insiders
Hansa Biopharma AB, formerly Hansa Medical AB, is a Sweden-based biopharmaceutical company with focus on immunomodulatory enzymes for treatment and prevention of rare and severe autoimmune conditions and transplant rejection. The Company’s operations consist of research and development for drug discovery. The Company conducts several projects, among which primary are IdeS (Immunoglobulin G-degrading enzyme of Streptococcus pyogenes) and HBP-assay (Heparin Binding Protein-assay). IdeS’s goal is to enable transplantation that prevents antibody-mediated rejection. HBP-assay is a diagnostic method that aims to predict severe sepsis in patients with infectious disease symptoms. The Company’s patent portfolio consists of several patent families that geographically cover numerous jurisdictions, including the United States, Europe and Japan.
Calendar
26/05/2024 - Roadshow
More about the company